Article Figures & Data
Figures
- FIGURE 1.
Increased sensitivity noted, with additional T3 vertebral body 68Ga-DOTATATE–positive lesion seen on coronal and axial images (left to right) not appreciated on patient’s morphologic MRI.
- FIGURE 2.
Persistent right-neck lymph node uptake on 68Ga-DOTATATE PET/CT (B) that has normal size and other morphologic criteria on correlative short-tau inversion recovery MRI (A).
- FIGURE 3.
Improved spatial and contrast resolution of pelvic lesions on coronal (left) and axial (right) 68Ga-DOTATATE PET/CT (A) compared with MIBG SPECT/CT (B).
- FIGURE 4.
Early progression in primary mass detected on 68Ga-DOTATATE PET/CT, with increase in volume not apparent on correlative MRI because of associated variable signal changes, edema, and necrosis. PET tumor thresholding allows accurate assessment of viable tumor volumes on axial PET images at, from left to right, initial staging, 2 mo, and 6 mo (A) and on coronal PET images at, from left to right, 2 and 6 mo (B).
- FIGURE 5.
(A) Resolution of bone marrow disease on 68Ga-DOTATATE PET/CT (from left to right: initial staging, 2 mo, and 6 mo). (B and C) Short-tau inversion recovery MRI still showing changes at 6 mo (false-positive MRI) (initial staging [B], 2 mo [C top], and 6 mo [C bottom]).
- FIGURE 6.
(A) Improved but persistent bony skull lesions (arrow) at, from left to right, initial staging, 2 mo, and 6 mo on 68Ga-DOTATATE PET. (B) These changes (arrow) are not well visualized, however, on correlative T1-weighted and fluid-attenuated inversion recovery MRI performed on same day at 6 mo.
- FIGURE 7.
Viable tumor volume delineation using thresholding techniques is more accurate and established on 68Ga-DOTATATE PET/CT (left) than on T1-weighted MRI (middle) or CT (right).
Tables
Characteristic Data Sex Male 3 Female 5 Age (mo) Median 30 Range 4–60 Histopathology High risk 7 Not available 1 Catecholamines Normal 0 Elevated 8 Cytogenetics Adverse 1 Not adverse 6 Not available 1 Baseline imaging MRI 8 123I-MIBG 4 PET 3 Baseline disease involvement Soft tissue/lymph node involvement 8 Bony metastatic lesions 5 Bone marrow involvement 3 Stage II 3 III 1 IV 4 Risk group Intermediate 4 High 4 Data are number unless otherwise indicated.
Patient no. Indication GA RT dose (mCi/MBq) Concurrent anatomic imaging Soft- tissue lesions Bony lesions Bone marrow involvement Conclusion Concordance 1 Restaging Yes 2.16/80 MRI Yes No No Metastatic disease Yes 2 Response Yes 2/74 MRI Yes No No mIR Yes 3 Staging Yes 2.3/85.5 Radiography, ultrasound, MRI Yes Yes Yes Metastatic disease Yes 4 Response Yes 1.24/46 MRI Yes Yes Yes mIR Yes 5 Response Yes 1.2/44.6 MRI Yes Yes Yes mIR Yes 6 Response No 1.74/64.4 MRI Yes Yes Yes PD Yes 7 Response No 2/73.7 MRI Yes Yes No mMR Yes 8 Response No 1.75/65 MRI Yes Yes No mIR Yes 9 Response Yes 2.65/98 MRI Yes No No mCR Yes 10 Response Yes 1.3/47 MRI Yes No No mIR Yes 11 Staging No 2.75/102 Radiography, ultrasound, MRI Yes Yes Yes Metastatic disease Yes 12 Response Yes 1.48/55 MRI Yes No No mIR Yes 13 Restaging Yes 1/37 MRI No Yes No Lesion on MRI not 68Ga-DOTATATE– avid More accurate response on PET 14 Staging Yes 2/74 CT, MRI Yes Yes No Numerous soft-tissue and bony lesions PET identified additional lesions 15 Response No 1.4/51.6 MRI No No No mCR Yes GA = general anesthesia; RT = radiopharmaceutical dose; mIR = metabolic incomplete response; PD = progressive disease; mMR = mixed metabolic response; mCR = complete metabolic response.
Supplemental Data
Files in this Data Supplement:
Supplemental Data
Files in this Data Supplement:
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.